Skip to Content

Trials of New Cancer Therapies Can’t Enroll Enough Patients

August 14, 2017

Engineering of human immune cells to fight off cancer promised to help cure the disease, and, so far, it appears to be living up to the hype. So you might think that enlisting patients to take part in trials of the new therapies would be easy. But the New York Times reports that there's a hitch. First, many biotech firms are creating similar and competing treatments. Second, they can't be offered to all patients, perhaps because their cancers are treated surgically or because they don't attend a hospital involved with research. Combined, those factors mean that many trials are failing to recruit enough people to obtain useful results—and it's even worse for targeted therapies.

Keep Reading

Most Popular

Geoffrey Hinton tells us why he’s now scared of the tech he helped build

“I have suddenly switched my views on whether these things are going to be more intelligent than us.”

Deep learning pioneer Geoffrey Hinton has quit Google

Hinton will be speaking at EmTech Digital on Wednesday.

Video: Geoffrey Hinton talks about the “existential threat” of AI

Watch Hinton speak with Will Douglas Heaven, MIT Technology Review’s senior editor for AI, at EmTech Digital.

Doctors have performed brain surgery on a fetus in one of the first operations of its kind

A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.